Published in Pharmacol Rev on June 01, 2012
Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol (2014) 2.73
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression. PLoS One (2013) 1.55
Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget (2014) 1.13
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res (2012) 1.11
Synthetic methods for the preparation of platinum anticancer complexes. Chem Rev (2013) 1.11
Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes. Cancer Res (2014) 1.11
An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett (2015) 1.05
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat Commun (2015) 1.03
MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G₁/S transition and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer (2014) 0.98
WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis. Sci Rep (2014) 0.90
The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy. Br J Cancer (2014) 0.89
Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death. Oncotarget (2015) 0.88
Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations. Cancer Med (2014) 0.88
Influence of nanoparticles of platinum on chicken embryo development and brain morphology. Nanoscale Res Lett (2013) 0.87
The association of transporter genes polymorphisms and lung cancer chemotherapy response. PLoS One (2014) 0.87
Downregulation of phosphoglycerate dehydrogenase inhibits proliferation and enhances cisplatin sensitivity in cervical adenocarcinoma cells by regulating Bcl-2 and caspase-3. Cancer Biol Ther (2015) 0.86
Cisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cells. Oncotarget (2015) 0.86
GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. BMC Cancer (2015) 0.86
Determinants for simultaneous binding of copper and platinum to human chaperone Atox1: hitchhiking not hijacking. PLoS One (2013) 0.85
Pharmacological and molecular effects of platinum(II) complexes involving 7-azaindole derivatives. PLoS One (2014) 0.85
Chloroquine-enhanced efficacy of cisplatin in the treatment of hypopharyngeal carcinoma in xenograft mice. PLoS One (2015) 0.85
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs (2013) 0.84
Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano (2013) 0.84
The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity. Mol Cancer Ther (2014) 0.83
Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. J Transl Med (2016) 0.83
Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther (2016) 0.83
Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design. Nat Commun (2015) 0.82
Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle. J Control Release (2015) 0.82
Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy. Int J Mol Sci (2015) 0.82
The combination of thioxodihydroquinazolinones and platinum drugs reverses platinum resistance in tumor cells by inducing mitochondrial apoptosis independent of Bax and Bak. Bioorg Med Chem Lett (2014) 0.82
Vasohibin 2 decreases the cisplatin sensitivity of hepatocarcinoma cell line by downregulating p53. PLoS One (2014) 0.82
Investigating the pretreatment miRNA expression patterns of advanced hepatocellular carcinoma patients in association with response to TACE treatment. Biomed Res Int (2015) 0.82
Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance. ChemMedChem (2014) 0.82
Higher expression of SIRT1 induced resistance of esophageal squamous cell carcinoma cells to cisplatin. J Thorac Dis (2015) 0.81
Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm Res (2014) 0.81
Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals. J Biol Inorg Chem (2013) 0.81
miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells. Cancer Sci (2016) 0.81
Nephroprotective effect of bee honey and royal jelly against subchronic cisplatin toxicity in rats. Cytotechnology (2015) 0.81
Chronic treatment with cisplatin induces replication-dependent sister chromatid recombination to confer cisplatin-resistant phenotype in nasopharyngeal carcinoma. Oncotarget (2014) 0.80
Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance. ChemMedChem (2014) 0.80
Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention. Mol Cancer (2017) 0.80
Stimulation of superoxide production increases fungicidal action of miconazole against Candida albicans biofilms. Sci Rep (2016) 0.80
MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin. Cancer Cell Int (2016) 0.79
Alkylating Agent-Induced NRF2 Blocks Endoplasmic Reticulum Stress-Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis. Mol Cancer Ther (2016) 0.79
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol (2014) 0.79
High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy. Oncotarget (2015) 0.79
Clostridium perfringens enterotoxin (CPE) and CPE-binding domain (c-CPE) for the detection and treatment of gynecologic cancers. Toxins (Basel) (2015) 0.79
Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin. Cancers (Basel) (2014) 0.78
The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin. Mol Pharm (2012) 0.78
Contributions of microRNA dysregulation to cisplatin resistance in adenocarcinoma cells. Exp Cell Res (2012) 0.78
Quercetin Enhances Cisplatin Sensitivity of Human Osteosarcoma Cells by Modulating microRNA-217-KRAS Axis. Mol Cells (2015) 0.78
P16(INK4A) is required for cisplatin resistance in cervical carcinoma SiHa cells. Oncol Lett (2014) 0.77
Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin. Oncotarget (2016) 0.77
Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer. Oncotarget (2017) 0.77
EGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy. Pharm Res (2015) 0.76
Cisplatin activates volume-sensitive like chloride channels via purinergic receptor pathways in nasopharyngeal carcinoma cells. J Membr Biol (2014) 0.76
Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment. Drug Des Devel Ther (2016) 0.76
Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer. Pharm Res (2016) 0.76
Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecol Oncol (2015) 0.76
Differential cytotoxicity induced by the Titanium(IV)Salan complex Tc52 in G2-phase independent of DNA damage. BMC Cancer (2016) 0.76
Cisplatin handover between copper transporters: the effect of reducing agents. J Biol Inorg Chem (2014) 0.76
DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer (2015) 0.76
Contribution of intracellular ATP to cisplatin resistance of tumor cells. J Biol Inorg Chem (2012) 0.76
Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget (2016) 0.75
Enhancement of Selectivity of an Organometallic Anticancer Agent by Redox Modulation. J Med Chem (2015) 0.75
Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. BMC Cancer (2017) 0.75
Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma. Oncol Rep (2016) 0.75
PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells. Oncotarget (2016) 0.75
Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs. J Biol Inorg Chem (2015) 0.75
FAT10 is associated with the malignancy and drug resistance of non-small-cell lung cancer. Onco Targets Ther (2016) 0.75
Antitumour action on human glioblastoma A1235 cells through cooperation of bee venom and cisplatin. Cytotechnology (2015) 0.75
WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance. Sci Rep (2017) 0.75
Acquired resistance of pancreatic cancer cells to cisplatin is multifactorial with cell context-dependent involvement of resistance genes. Cancer Gene Ther (2016) 0.75
Reduction of Dacarbazine cytogenetic effects on somatic cells in male mice using bee glue (Propolis) to manifest the scientific miracles in the Quran. Electron Physician (2016) 0.75
Platinum-Based Drugs and DNA Interactions Studied by Single-Molecule and Bulk Measurements. Biophys J (2016) 0.75
Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. J Inorg Biochem (2015) 0.75
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. BBA Clin (2014) 0.75
MiR-23b controls ALDH1A1 expression in cervical cancer stem cells. BMC Cancer (2017) 0.75
Nano-mechanical Phenotype as a Promising Biomarker to Evaluate Cancer Development, Progression, and Anti-cancer Drug Efficacy. J Cancer Prev (2016) 0.75
Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes. Bioinorg Chem Appl (2016) 0.75
Proteasome Inhibitor YSY01A Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant Human Ovarian Cancer Cells. J Cancer (2016) 0.75
Long-term exposure to estrogen enhances chemotherapeutic efficacy potentially through epigenetic mechanism in human breast cancer cells. PLoS One (2017) 0.75
A novel mathematical model describing adaptive cellular drug metabolism and toxicity in the chemoimmune system. PLoS One (2015) 0.75
TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells. Oncol Lett (2016) 0.75
The role and mechanism of WEE1 on the cisplatin resistance reversal of the HepG2/DDP human hepatic cancer cell line. Oncol Lett (2015) 0.75
Altered glutamine metabolism in platinum resistant ovarian cancer. Oncotarget (2016) 0.75
Transcriptome analysis indicates TFEB1 and YEATS4 as regulatory transcription factors for drug resistance of ovarian cancer. Oncotarget (2015) 0.75
Microdose-induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther (2016) 0.75
Fullerene C60 Penetration into Leukemic Cells and Its Photoinduced Cytotoxic Effects. Nanoscale Res Lett (2017) 0.75
Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. PLoS One (2016) 0.75
MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochim Biophys Acta (2016) 0.75
Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment. Clin Epigenetics (2016) 0.75
Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study. Int J Oncol (2017) 0.75
API5 induces cisplatin resistance through FGFR signaling in human cancer cells. Exp Mol Med (2017) 0.75
MicroRNA-20a contributes to cisplatin-resistance and migration of OVCAR3 ovarian cancer cell line. Oncol Lett (2017) 0.75
Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells. Oncol Lett (2017) 0.75
JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Oncogenesis (2017) 0.75
A Diagnostic Microdosing Approach to Investigate Platinum Sensitivity in Non-Small Cell Lung Cancer. Int J Cancer (2017) 0.75
Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. PLoS One (2017) 0.75
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 32.82
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
microRNA functions. Annu Rev Cell Dev Biol (2007) 15.74
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol (2006) 11.16
Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 10.74
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Translational control in stress and apoptosis. Nat Rev Mol Cell Biol (2005) 8.91
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Mechanisms of cancer drug resistance. Annu Rev Med (2002) 7.91
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science (2005) 5.04
MicroRNA functions in stress responses. Mol Cell (2010) 4.46
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res (2008) 3.56
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A (2002) 3.28
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer (2007) 3.24
Platinum resistance: the role of DNA repair pathways. Clin Cancer Res (2008) 3.16
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol (2008) 2.69
Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol (2008) 2.56
B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell (2010) 2.44
Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. Cell Cycle (2010) 2.41
Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A (2009) 2.35
MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26
Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A (2011) 2.22
Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem (2002) 2.20
The mechanism of action of antitumor platinum compounds. Prog Nucleic Acid Res Mol Biol (1979) 2.19
Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain. Cell (2010) 2.17
TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell (2011) 2.13
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev (1998) 2.11
Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer (2010) 2.10
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol (2010) 1.99
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer (1998) 1.94
MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene (2011) 1.94
miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer (2010) 1.76
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol (2006) 1.75
MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet (2011) 1.71
Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun (2010) 1.67
The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol (2002) 1.62
Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res (2011) 1.59
Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene (2002) 1.59
Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol (2000) 1.58
SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci U S A (2009) 1.56
Hsp90: a chaperone for protein folding and gene regulation. Biochem Cell Biol (2005) 1.51
Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res (2003) 1.48
miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2. Med Oncol (2011) 1.48
Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress (2007) 1.46
Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer (2010) 1.40
Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften (1973) 1.39
miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol (2011) 1.39
Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett (2007) 1.38
Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J Mol Cell Cardiol (2003) 1.34
MicroRNAs and cellular phenotypy. Cell (2010) 1.34
BRCA mutations in the management of breast cancer: the state of the art. Nat Rev Clin Oncol (2010) 1.32
Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem (2001) 1.31
SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res (2008) 1.30
Transport of cisplatin by the copper efflux transporter ATP7B. Mol Pharmacol (2007) 1.30
Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res (2010) 1.30
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res (2010) 1.29
The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J Biol Chem (1995) 1.28
Spectrum of cisplatin-induced mutations in Escherichia coli. Proc Natl Acad Sci U S A (1987) 1.28
IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene (2009) 1.27
MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci (2011) 1.27
Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res (2010) 1.26
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A (2010) 1.25
Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res (2007) 1.25
Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J Pathol (2010) 1.24
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23
Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res (2010) 1.20
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer (2009) 1.19
Targeting NF-kappaB signaling pathway suppresses tumor growth, angiogenesis, and metastasis of human esophageal cancer. Mol Cancer Ther (2009) 1.18
AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res (2010) 1.17
Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer (1995) 1.16
Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res (2006) 1.16
Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg (2011) 1.14
Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents (2005) 1.13
Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res (2002) 1.13
Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br J Cancer (2003) 1.12
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res (1993) 1.11
Knockdown of Snail, a novel zinc finger transcription factor, via RNA interference increases A549 cell sensitivity to cisplatin via JNK/mitochondrial pathway. Lung Cancer (2008) 1.11
Heterogeneous SWI/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma. Oncogene (2009) 1.09
Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res (2004) 1.08
p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One (2011) 1.06
Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer (1999) 1.06
Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles. Mol Cancer (2007) 1.06
MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance. Head Neck (2010) 1.06
Short interfering RNA directed against TWIST, a novel zinc finger transcription factor, increases A549 cell sensitivity to cisplatin via MAPK/mitochondrial pathway. Biochem Biophys Res Commun (2008) 1.04
Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors. Mol Cancer (2004) 1.04
Rab35 mediates transport of Cdc42 and Rac1 to the plasma membrane during phagocytosis. Mol Cell Biol (2010) 1.04
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
P-glycoprotein: from genomics to mechanism. Oncogene (2003) 3.66
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
Sex-specific fitness effects of nutrient intake on reproduction and lifespan. Curr Biol (2008) 2.32
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26
Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res (2007) 1.91
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther (2009) 1.83
Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol (2008) 1.80
A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta (2009) 1.79
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
Silent (synonymous) SNPs: should we care about them? Methods Mol Biol (2009) 1.61
The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013) 1.54
Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med (2008) 1.54
Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat (2012) 1.53
Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines. Cancer Res (2003) 1.48
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res (2009) 1.38
Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol Sci (2009) 1.37
Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat (2012) 1.35
Human ABCB6 localizes to both the outer mitochondrial membrane and the plasma membrane. Biochemistry (2007) 1.33
SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res (2008) 1.30
Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A (2010) 1.25
Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther (2004) 1.24
A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol (2009) 1.22
Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nat Rev Drug Discov (2009) 1.22
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther (2008) 1.19
Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A (2006) 1.18
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol (2004) 1.18
Manganese transport and trafficking: lessons learned from Saccharomyces cerevisiae. Eukaryot Cell (2005) 1.18
Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells. J Med Chem (2009) 1.17
Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res (2006) 1.16
The sounds of silence: synonymous mutations affect function. Pharmacogenomics (2007) 1.14
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13
Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol (2002) 1.13
The dynamics of drug resistance: a mathematical perspective. Drug Resist Updat (2012) 1.12
Principal expression of two mRNA isoforms (ABCB 5alpha and ABCB 5beta ) of the ATP-binding cassette transporter gene ABCB 5 in melanoma cells and melanocytes. Pigment Cell Res (2005) 1.12
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res (2012) 1.11
P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res (2003) 1.08
Studies with novel Pdr5p substrates demonstrate a strong size dependence for xenobiotic efflux. J Biol Chem (2002) 1.08
The transcription factor Erg regulates expression of histone deacetylase 6 and multiple pathways involved in endothelial cell migration and angiogenesis. Blood (2011) 1.07
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res (2009) 1.05
Structure of a multidrug transporter. Nat Biotechnol (2009) 1.04
MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res (2013) 1.04
Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. J Cell Physiol (2005) 1.04
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci U S A (2011) 1.03
Identification of cytoskeletal [14C]carboplatin-binding proteins reveals reduced expression and disorganization of actin and filamin in cisplatin-resistant cell lines. Mol Pharmacol (2004) 1.01
Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol (2011) 1.01
Sensitive measurement of single-nucleotide polymorphism-induced changes of RNA conformation: application to disease studies. Nucleic Acids Res (2012) 1.00
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
A novel way to spread drug resistance in tumor cells: functional intercellular transfer of P-glycoprotein (ABCB1). Trends Pharmacol Sci (2005) 0.98
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos (2010) 0.98
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A (2013) 0.96
Down-regulation of a manganese transporter in the face of metal toxicity. Mol Biol Cell (2009) 0.96
Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells. Stem Cells (2012) 0.95
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res (2012) 0.95
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
Minipig and beagle animal model genomes aid species selection in pharmaceutical discovery and development. Toxicol Appl Pharmacol (2013) 0.94
Sex differences in nutrient-dependent reproductive ageing. Aging Cell (2009) 0.94
Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics (2007) 0.93
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood (2013) 0.92
Local adaptation of sex induction in a facultative sexual crustacean: insights from QTL mapping and natural populations of Daphnia magna. Mol Ecol (2013) 0.91
High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences. Hum Gene Ther (2003) 0.91
Elemental tomography of cancer-cell spheroids reveals incomplete uptake of both platinum(II) and platinum(IV) complexes. J Am Chem Soc (2007) 0.91
Transmembrane inhibitors of P-glycoprotein, an ABC transporter. J Med Chem (2005) 0.91
In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer. Hum Gene Ther (2002) 0.90
Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1. Drug Resist Updat (2012) 0.90
Identification by functional cloning from a retroviral cDNA library of cDNAs for ribosomal protein L36 and the 10-kDa heat shock protein that confer cisplatin resistance. Mol Pharmacol (2006) 0.90
Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity. Cancer (2013) 0.90
P-Glycoprotein is not present in mitochondrial membranes. Exp Cell Res (2007) 0.89
A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. J Inorg Biochem (2004) 0.89
Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein. J Med Chem (2011) 0.89
Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm (2011) 0.88
Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol (2010) 0.88
Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro. Biotechniques (2004) 0.88
Overlapping substrate and inhibitor specificity of human and murine ABCG2. Drug Metab Dispos (2013) 0.88
Performance is no proxy for genetic quality: trade-offs between locomotion, attractiveness, and life history in crickets. Ecology (2010) 0.88
Collateral sensitivity of multidrug-resistant cells to the orphan drug tiopronin. J Med Chem (2011) 0.88
An SNP-based second-generation genetic map of Daphnia magna and its application to QTL analysis of phenotypic traits. BMC Genomics (2014) 0.88
SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy. Curr Pharm Biotechnol (2004) 0.87
RAB8 enhances TMEM205-mediated cisplatin resistance. Pharm Res (2011) 0.87